Ozden OZCAN, Yusuf METİN, Suzan ÇINAR, Gunnur DENİZ, Melıh AKTAN

Intracellular Levels of IL-10 and STAT3 in Patients with Chronic Lymphocytic Leukemia

Objective: Chronic Lymphocytic Leukemia (CLL) is characterized by the accumulation of CD5+CD19+ B cells in the bone marrow and peripheral blood. Recent studies indicated that expression of IL-10, AID and mir-155 which are regulated by STAT3 are increased in CLL patients. CD5+CD19+ regulator B (Breg) cells secrete IL-10 and suppress the immune system. While the CLL cells show similar immunophenotypic properties to Breg cells, they are also thought to be functionally similar. In this study, STAT3 and IL-10 levels of CLL patients were investigated. Methods: Peripheral blood samples obtained from patients (n:24) and healthy controls (n:14). Peripheral blood mononuclear cells were cultured for 48 hours in the presence and absence of CpG for IL-10 expression and cultured with and without PMA for STAT3 expression. IL-10 and STAT3 expression were analyzed with anti-CD5, anti-CD19, anti-CD38, anti-STAT3 and anti-IL-10 monoclonal antibodies by using flow cytometry. Results: Compared to healthy subjects, increased IL-10+, IL-10+CD19+, STAT3+CD19+ were obtained in lymphocyte population of patients. Increased IL-10 was showed CD19+ B cells of CLL patients. Our results showed that IL-10 levels had no significant difference between CD5+CD19+ cells, whereas STAT3 levels were found lower in patient compared to healthy controls. Conclusion: These results made us thought that the levels of IL-10 and STAT3 expression in CLL B cells is clearly different from normal B lymphocytes might have a role in the biology of CLL. It is believed that the presented data will contribute to the studies that scrutinize the similarity of CLL cells to Breg cells.

Keywords:

CLL, IL-10, STAT3, Breg, flow cytometry,

PDF

___

Hallek M and Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679–1705. DOI:10.1002/ajh.26367.
Maliha K, Rabbia S, Philip AT. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol. 2018; 97(1):1-15. DOI: 10.1007/s00277-017-3149-9.
Catalán D. Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillon JC and Aravena O. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12:611795. DOI:10.3389/fimmu.2021.611795.
Zhao Q and Jung LK. Frequency of CD19+ CD24hiCD38hi regulatory B cells is decreased in peripheral blood and synovial fluid of patients with juvenile idiopathic arthritis: a preliminary study. Pediatric Rheumatol Online J. 2018;16(1):44. DOI:10.1186/s12969-018-0262-9.
Saulep-Easton D, Vincent FB, Quah PS, Wei A, Ting SB, Croce CM. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B-cells. Leukemia 2016; 30(1):163-172. DOI: 10.1038/leu.2015.174.
Rutz S, Ouyang W. Regulation of interleukin-10 expression. Adv Exp Med Bio. 2016; 941:89-116. DOI: 10.1007/978-94-024-0921-5_5.
Juliane L, Victor S, Johannes H, Christoph G. Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers (Basel). 2019;11(11): 1704. DOI: 10.3390/cancers11111704.
Liqun Y, Pengfei S, Gaichao, Zhao G, Xu J, Peng W, Zhang J, Zhang G,Wang X, Dong Z, Chen F and Cui H. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020; 5: 8. DOI:10.1038/s41392-020-0110-5.
Wook J. Role of JAK/STAT3 Signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial–mesenchymal transition. Cells 2020; 9(1): 217. DOI:10.3390/cells9010217.
Chikuma S, Kanamori M, Mise-Omata S, Yoshimura A. Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer 2017; 108:574–580. DOI:10.1111/cas.13194.
Daniel EJ, Rachel A. O’K, Jennifer RG. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018; 15(4): 234–248. DOI:10.1038/nrclinonc.2018.8.
DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013; 27(1):170-182. DOI: 10.1038/leu.2012.165.
Bewarder M, Stilgenbauer S, Thurner L, Kaddu-Mulindwa D. Current treatment options in CLL. Cancers (Basel). 2021; 13(10): 2468. DOI:10.3390/cancers13102468
Alkan S. Kronik lenfositik lösemi (KLL): patogenezi ve biyolojisi. Türk Hematoloji Derneği. http://www.thd.org.tr/thdData/userfiles/file/kroniklenfositik.pdf7. 2006. (Turkish)
Gupta R, Garg N. and Singh A. Anti-globulin test positivity indicates advanced disease in Indian CLL patients. Am J Blood Res. 2021; 11(2): 157–162.
Liu Y. Liao S, Bennett S, Tang H, Song D, Wood D, Zhan X, and Xu J. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 2021; 54(2): e12974. DOI: 10.1111/cpr.12974.
Zhao J, FenQi Y, RongYu Y. STAT3: A key regulator in liver fibrosis. Annals of Hepatology 2021;100224. DOI:10.1016/j.aohep.2020.06.010.
Antosz H, Wojciechowska K, Sajewicz J, Choroszynska D, Marzec-Kotarska B, Osiak M. IL-6, IL-10, c-Jun and STAT3 expression in B-CLL. Blood Cells Mol Dis. 2015; 54(3):258-265. DOI:10.1016/j.bcmd.2014.11.006.
Gary-Gouy H, Harriague J, Bismuth G, Platze, C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002; 100:4537-4543. DOI:10.1182/blood-2002-05-1525.